The long-term prognosis after surgical resection of malignant insulinoma (INS) is poor. Novel adjuvant therapies, specifically targeting cancer stem cells (CSCs), are warranted. Therefore, the goal of this study was to characterize and target putative INS CSCs. Using fluorescence-activated cell sorting, human INS cell line CM and pancreatic carcinoid cell line BON1 were screened for the presence of stem cell-associated markers. CD90, CD166, and GD2 were identified as potential CSC markers. Only CD90+ INS cells had an increased tumor-initiating potential in athymic nude mice. Anti-CD90 monoclonal antibodies decreased the viability and metastatic potential of injected cells in a zebrafish embryo INS xenograft model. Primary INS stained positive for CD90 by immunohistochemistry, however also intratumoral fibroblasts and vascular endothelium showed positive staining. The results of this study suggest that anti-CD90 monoclonals form a potential novel adjuvant therapeutic modality by targeting either INS cells directly, or by targeting the INS microenvironment.
Get full access to this article
View all access options for this article.
References
1.
MehrabiA, FischerL, HafeziM, DirlewangerA, GrenacherL, DinerMK, FonouniH, GolrizM, GaroussiC, et al. (2014). A systematic review of localization, surgical treatment options, and outcome of insulinoma. Pancreas, 43:675–686.
2.
OkabayashiT, ShimaY, SumiyoshiT, KozukiA, ItoS, OgawaY, KobayashiM and HanazakiK. (2013). Diagnosis and management of insulinoma. World J Gastroenterol, 14:829–837.
3.
DanforthDNJr., GordenP and BrennanMF. (1984). Metastatic insulin-secreting carcinoma of the pancreas: clinical course and the role of surgery. Surgery, 96:1934–1938.
4.
GramaD, ErikssonB, MartenssonH, CedermarkB, AhrénB, KristofferssonA, RastadJ, ObergK and AkerströmG. (1992). Clinical characteristics, treatment and survival in patients with pancreatic tumors causing hormonal syndromes. World J Surg, 16:632–639.
5.
BaccelliI and TrumppA. (2012). The evolving concept of cancer and metastasis stem cells. J Cell Biol, 198:281–293.
6.
VisvaderJE. (2011). Cells of origin in cancer. Nature, 469:314–322.
7.
Van der MeulenT and HuisingMO. (2014). Maturation of stem cell-derived beta-cells guided by the expression of urocortin 3. Rev Diabet Stud, 11:115–132.
ManiSA, GuoW, LiaoM-J, EatonEN, AyyananA, ZhouAY, BrooksM, ReinhardF, ZhangCC, et al. (2008). The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell, 133:704–715.
10.
LanL, LuoY, CuiD, ShiBY and DengW. (2013). Epithelial-mesenchymal transition triggers cancer stem cell generation in human thyroid cancer cells. Int J Oncol, 43:113–120.
11.
FendrichV, MaschuwK, WaldmannJ, BuchholzM, RehmJ, GressTM, BartschDK and KönigA. (2012). Epithelial-mesenchymal transition is a critical step in tumorgenesis of pancreatic neuroendocrine tumors. Cancers, 4:281–294.
12.
GrandeE, CapdevilaJ, BarriusoJ, Antón-AparicioL and CastellanoD. (2012). Gastroenteropancreatic neuroendocrine tumor cancer stem cells: do they exist?. Cancer Metastasis Rev, 31:47–53.
13.
RegitinigP, SpullerE and DenkH. (2001). Insulinoma of the pancreas with insular-ductular differentiation in its liver metastasis—indication of a common stem-cell origin of the exocrine and endocrine components. Virchows Arch, 438:624–628.
14.
BuishandFO, KirpensteijnJ, JaarsmaAA, SpeelEJM, KikM and MolJA. (2013). Gene expression profiling of primary canine insulinomas and their metastases. Vet J, 197:192–197.
15.
SadanandamA, WullschlegerS, LyssiotisCA, GrötzingerC, BarbiS, BersaniS, KörnerJ, WafyI, MafficiniA, et al. (2015). A cross-species analysis in pancreatic neuroendocrine tumors reveals molecular subtypes with distinctive clinical, metastatic, developmental, and metabolic characteristics. Cancer Discov, 5:1296–1313.
16.
YangZF, HoDW, NgMN, LauCK, YuWC, NgaiP, ChuPW, LamCT, PoonRT and FanST. (2008). Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell, 13:153–166.
17.
TangKH, DaiYD, TongM, ChanYP, KwanPS, FuL, QinYR, TsaoSW, LungHL, et al. (2013). A CD90(+) tumor-initiating cell population with an aggressive signature and metastatic capacity in esophageal cancer. Cancer Res, 73:2322–2332.
18.
HeJ, LiuY, ZhuT, ZhuJ, DimecoF, VescoviAL, HethJA, MuraskoKM, FanX and LubmanDM. (2012). CD90 is identified as a candidate marker for cancer stem cells in primary high-grade gliomas using tissue microarrays. Mol Cell Proteomics, 11:M111 010744.
19.
LobbaAR, ForniMF, CarreiraAC and SogayarMC. (2012). Differential expression of CD90 and CD14 stem cell markers in malignant breast cancer cell lines. Cytometry A, 81:1084–1091.
20.
YanX, LuoH, ZhouX, ZhuB, WangY and BianX. (2013). Identification of CD90 as a marker for lung cancer stem cells in A549 and H446 cell lines. Oncol Rep, 30:2733–2740.
21.
SaalbachA, WetzelA, HausteinUF, StichterlingM, SimonJC and AndereggU. (2005). Interaction of human Thy-1 (CD90) with the integrin alphavbeta3 (CD51/CD61): an important mechanism mediating melanoma cell adhesion to activated endothelium. Oncogene, 24:6526–6532.
22.
BrinkhofB, SpeeB, RothuizenJ and PenningLC. (2006). Development and evaluation of canine reference genes for accurate quantification of gene expression. Anal Biochem, 356:36–43.
23.
LawsonND and WeinsteinBM. (2002). In vivo imaging of embryonic vascular development using transgenic zebrafish. Dev Biol, 248:307–318.
24.
SabaawyHE, AzumaM, EmbreeLJ, TsaiHJ, StarostMF and HicksteinDD. (2006) TEL-AML1 transgenic zebrafish model of precursor B cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A, 103:15166–15171.
25.
KunzPL. (2015). Carcinoid and neuroendocrine tumors: building on success. J Clin Oncol, 33:1855–1863.
26.
RussellWMS and BurchRL. (eds). (1959). The Principles of Humane Experimental Techniques. Methuen, London.
27.
HerreraMB, BrunoS, ButtiglieriS, TettaC, GattiS, DeregibusMC, BussolatiB and CamussiG. (2006). Isolation and characterization of a stem cell population from adult human liver. Stem Cells, 24:2840–2850.
28.
SaalbachA, WetzigT, HausteinUF and AndereggU. (1999). Detection of human soluble Thy-1 in serum by ELISA. Fibroblasts and activated endothelial cells are a possible source of soluble Thy-1 in serum. Cell Tissue Res, 298:307–315.
29.
UllahI, SubbaraoRB and RhoGJ. (2015). Human mesenchymal stem cells—current trends and future prospective. Biosci Rep, 35:e00191.
30.
VidalM, MorrisR, GrosveldF and SpanopoulouE. (1990). Tissue-specific control elements of the Thy-1 gene. EMBO J, 9:833–840.
31.
RegeTA and HagoodJS. (2006). Thy-1 as a regulator of cell-cell and cell-matrix interactions in axon regeneration, apoptosis, adhesion, migration, cancer, and fibrosis. FASEB J, 20:1045–1054.
32.
JiangJ, ZhangY, ChuaiS, WangZ, ZhengD, XuF, ZhangY, LiC, LiangY and ChenZ. (2012). Trastuzumab (herceptin) targets gastric cancer stem cells characterized by CD90 phenotype. Oncogene, 31:671–682.
33.
ChengBQ, JiangY, LiDL, FanJJ and MaM. (2012). Up-regulation of thy-1 promotes invasion and metastasis of hepatocarcinomas. Asian Pac J Cancer Prev, 13:1349–1353.
34.
ChenWC, ChangYS, HsuHP, YenMC, HuangHL, ChoCY, WangCY, WengTY, LaiPT, et al. (2015). Therapeutics targeting CD90-integrin-AMPK-CD133 signal axis in liver cancer. Oncotarget, 6:42923–42937.
35.
BaroniMG, CavalloMG, MarkM, MonetiniL, StoehrerB and PozzilliP. (1999). Beta-cell gene expression and functional characterization of the human insulinoma cell line CM. J Endocrinol, 161:59–68.
36.
EversBM, IshizukaJ, TownsendCMJr., and ThompsonJC. (1994). The human carcinoid cell line, BON. A model system for the study of carcinoid tumors. Ann N Y Acad Sci, 733:393–406.
37.
LiJ, LiuH, YuJ and YuH. (2015). Chemoresistance to doxorubicin induces epithelial-mesenchymal transition via upregulation of transforming growth factor β signaling in HCT116 colon cancer cells. Mod Med Rep, 12:192–198.
38.
PirozziG, TirinoV, CamerlingoR, FrancoR, La RoccaA, LiguoriE, MartucciN, PainoF, NormannoN and RoccoG. (2011). Epithelial to mesenchymal transition by TGFβ-1 stemness characteristics in primary non small cell lung cancer cell line. PLoS One, 6:e21548.
39.
BeuranM, NegoiI, PaunS, IonAD, BleotuC, NegoiR and HostiucS. (2015). The epithelial to mesenchymal transition in pancreatic cancer: a systematic review. Pancreatology, 15:217–225.
40.
LuH, ClauserKR, TamWL, FröseJ, YeX, EationEN, ReinhardtF, DonnenbergVS, BhargavaR, CarrSA and WeinbergRA. (2014). A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages. Nat Cell Biol, 16:1105–1117.
41.
IshiuraY, KotaniN, YamashitaR, YamamotoH, KozutsumiY and HonkeK. (2010). Anomalous expression of Thy1 (CD90) in B-cell lymphoma cells and proliferation inhibition by anti-Thy1 antibody treatment. Biochem Biophys Res Commun, 396:329–334.
42.
FujitaN, KatoY, NaitoM and TsuruoT. (1996). A novel anti-Thy-1 (CD90) monoclonal antibody induces apopotosis in mouse malignant T-lymphoma cells in spite of inducing bcl-2 expression. Int J Cancer, 66:544–550.
43.
ZhuJ, ThakolwiboonS, LiuX, ZhangM and LubmanDM. (2014). Overexpression of CD90 (Thy-1) in pancreatic adenocarcinoma present in the tumor microenvironment. PLoS One, 9:e115507.
44.
DirekzeNC, Hodivala-DilkeK, JefferyR, HuntT, PoulsomR, OukrifD, AlisonMR and WrightNA. (2004). Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts. Cancer Res, 64:8492–8495.
45.
AbboudB and BoujaoudeJ. (2008) Occult sporadic insulinoma: localization and surgical strategy. World J Gastroenterol, 14:657–665.
46.
FoygelK, WangH, MachtalerS, LutzAM, ChenR, PyszM, LoweAW, TianL, CarriganT, BrentnallTA and WillmannJK. (2013). Detection of pancreatic ductal adenocarcinoma in mice by ultrasound imaging of thymocyte differentiation antigen 1. Gastroenterology, 145:885–894.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
